BioTherapeutics | 1800 Kraft Dr., Suite 200, Blacksburg, VA, 24060

The next frontier in precision medicine and health innovation for preventing and treating inflammation and metabolic disease.

BioTherapeutics CEO Named 2017 Innovator of the Year by Roanoke-Blacksburg Technology Council
BioTherapeutics CEO Named 2017 Innovator of the Year by Roanoke-Blacksburg Technology Council BLACKSBURG, VA. April 24, 2017 —The Roanoke-Blacksburg Technology Council (RBTC)...
News / April 24 2017
BioTherapeutics Recruits Director of Translational Informatics and Scientific Director
BLACKSBURG, VA. April 1, 2017 —BioTherapeutics, Inc. (BTI) announced today that Drs. Pinyi Lu and Andrew Leber have joined the company to lead efforts aimed at broadening BTI’s...
News / April 06 2017
A Vision for Personalized Medicine and Health
BLACKSBURG, VA. March 22, 2017 – Studying the human immune system is like trying to work a vast, multidimensional jigsaw puzzle with pieces that are constantly changing shape. Billions...
News / March 22 2017

Our Purpose

Biotherapeutics Inc. (BTI) is a science-based biotechnology company that integrates Nutritionals, Therapeutics and IT to advance interventions for preventing and treating autoimmune and metabolic diseases.

See more about us
LANCL2: A Novel Therapeutic Target for Influenza
BLACKSBURG, VA. February 28, 2017—The BioTherapeutics (BTI) team has recently explored the potential of activating lanthionine synthetase C-like 2 (LANCL2) to treat infectious diseases,...
News / February 28 2017
NLRX1: A New Therapeutic Target for Inflammatory Bowel Disease
BLACKSBURG, VA. February 27, 2017 – The BioTherapeutics team recently characterized a new mechanism of action underlying the regulation of immunity and metabolism by nucleotide...
News / February 28 2017
Watch TEDx:Accelerated Path to Cures
BioTherapeutics CEO provides message of hope to IBD patients
News / February 09 2017
LANCL2 Modulates Immune Responses to Gastrointestinal Bacteria
BLACKSBURG, VA—01-15-2017—Lanthionine synthetase C-like 2 (LANCL2) has been validated as a therapeutic target for inflammatory bowel disease (IBD). New research shows that LANCL2 is...
News / January 15 2017
Solving Immunology to Accelerate Drug Development
BLACKSBURG, VA, Dec. 15, 2016 — “Solving Immunology?” has been accepted for publication in Trends in Immunology. The review is the culmination of the “Complex Systems Science,...
News / December 15 2016

Now Hiring

Interested in becoming a part of the BTI team? Take a look at our job openings

View all positions
Business Brief asks Presidents, CEOs, Owners and Leaders of companies located at the Virginia Tech Corporate Research Center (VTCRC) one question… “What key lesson have you...
News / November 23 2016
TEDx Talk Gives Spark of Hope to Inflammatory Bowel Disease Sufferers
BLACKSBURG, VA, November 15, 2016 – Last Friday, more than 600 people heard a message of hope and inspiration from Dr. Josep Bassaganya-Riera who presented his TEDx talk about the sparks...
News / November 15 2016
New Study Identifies BT-11 as a First-in-Class Oral Therapeutic for Inflammatory Bowel Disease
BLACKSBURG, Va. Nov. 4th, 2016—The oral, small-molecule therapeutic known as BT-11 is on the fast track to becoming the new drug for treating inflammatory bowel disease (IBD), a...
News / November 04 2016


NIMML uses innovation to tackle challenges in infectious, immune-mediated, and chronic inflammatory disease research. BTI was founded in 2008 by Dr. Josep Bassaganya-Riera as a result of the technology developed at VT’s Nutritional Immunology and Molecular Medicine Laboratory (NIMML).

Go to NIMML Website